SAPIEN 3 Transcatheter Aortic Valve Replacement Compared with Surgery in Intermediate-Risk Patients: A Propensity Score Analysis

Vinod H. Thourani, MD on behalf of The PARTNER Trial Investigators

ACC 2016 | Chicago | April 3, 2016



Disclosure Statement of Financial Interest



Vinod H. Thourani, MD

Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.

Affiliation/Financial Relationship

- Grant/Research Support
- Consulting Fees/Honoraria
- Major Stock Shareholder/Equity


Company

- Boston Scientific, Claret Medical, Edwards Lifesciences, Medtronic, St. Jude Medical
- Abbott Vascular, Edwards Lifesciences, St. Jude Medical
- None

The PARTNER 2A and S3i Trials Study Design



Intermediate Risk Symptomatic Severe Aortic Stenosis



Primary Endpoint: All-Cause Mortality, All Stroke, or Mod/Sev AR at One Year (Non-inferiority Propensity Score Analysis)

Quintile Propensity Score Analysis: Primary Endpoint



Surgery		TAVR			
# Patients	Mortality, Stroke, AR <u>></u> Mod	# Patients	Mortality, Stroke, AR <u>></u> Mod	Proportional Difference	Weighting
191	28.3%	138	13.8%	-14.5%	0.14
175	22.9%	171	9.9%	-12.9%	0.18
147	19.7%	197	10.7%	-9.1%	0.20
126	23.0%	219	14.6%	-8.4%	0.23
108	19.4%	238	15.1%	-4.3%	0.25


Overall weighted difference of proportions - 9.2% [-12.4%,-6.0%] two-sided 90% CI **Primary Endpoint - Non-inferiority** Death, Stroke, or AR ≥ Mod at 1 Year (VI)



Weighted Difference -9.2% Upper 1-sided 95% CI -6.0%

Non-Inferiority p-value < 0.001






Primary Non-Inferiority Endpoint Met

Primary Endpoint - Superiority Death, Stroke, or AR ≥ Mod at 1 Year (VI)




Weighted Difference -9.2% Upper 2-sided 95.0% CI -5.4% Superiority Testing p-value < 0.001



Superiority Achieved


Superiority Analysis Components of Primary Endpoint (VI)





Unadjusted Time-to-Event Analysis All-Cause Mortality and All Stroke (AT)





The PARTNER 2A and S3i Trials Conclusions



- In intermediate-risk patients, SAPIEN 3 TAVR resulted in low 1-year rates of all-cause mortality (7.4%), all stroke (4.6%), and moderate or severe aortic regurgitation (1.5%)
- A rigorous propensity score analysis comparing SAPIEN 3 TAVR with surgery from PARTNER 2A in intermediate-risk patients at 1 year demonstrated:
 - Non-inferiority for the primary endpoint (composite of all-cause mortality, all stroke, or AR ≥ moderate)
 - Superiority of SAPIEN 3 TAVR for the primary endpoint, all-cause mortality, and all stroke
 - Superiority of surgery for $AR \ge moderate$
- Time-to-event analyses indicated that the benefits of SAPIEN 3 TAVR occurred in the first few months, suggesting procedure-related effects

The PARTNER 2A and S3i Trial Clinical Implications



 The conclusions from the PARTNER 2A randomized trial and this propensity score analysis provide strong evidence that in intermediate-risk patients with severe aortic stenosis, SAPIEN 3 TAVR compared with surgery improves clinical outcomes and is the preferred therapy.